Editas Medicine, Inc. EDIT

RPD Designation Program Sunset Provisions

According to the current statutory sunset provisions for the Rare Pediatric Disease Priority Review Voucher Program, after September 30, 2020, FDA may only award a voucher for an approved rare pediatric disease product application if the sponsor has rare pediatric disease designation for the drug, and that designation was granted by September 30, 2020. After September 30, 2022, FDA may not award any rare pediatric disease priority review vouchers.

Fret not this is healthy trading, could you imagine if they update 101 and file IND for 301 in the same quarter. Magnificent, brilliant and ingenious to say the least

Consolidation and sympathy for our friend CRSPR

All flight attendants prepare for take off. Target altitude $60.00. Copy

This is not a quarter by quarter play. CRISPR is a infancy stage mega trend that will help the world immensely from a curative and agricultural point of view.

Feels good to be here

ARK holds 10% of the company at this point.

It was already leaning towards Editas from what is rumored.

Although the masses are ignorant to the studies and science it is only a matter of time before a major breakthrough becomes news before it becomes NEWS. The sector this small cap and its peers are getting more and more attention. Which gives the stocks more and more traction and trajectory.

Love it $$$$$$$$$$$$$$EDIT$$$$$$$$$$$$$$$$$$